MediciNova misses both Phase 2 endpoints despite HDL gains

Both prespecified Phase 2 endpoints missed their placebo comparisons, as MediciNova, Inc. NASDAQMNOV TYO4875 reported on Monday that tipelukast had not significantly reduced liver fat or fasting triglycerides after 24 weeks. The study enrolled 40 patients, and HDL cholesterol rose 5.7 mg/dL more on the drug than on placebo, a secondary result that leaves the main misses intact.

A November 2025 enrollment notice identified liver fat, measured by FibroScan, and fasting triglycerides as co-primary endpoints at week 24. In Monday's results, the liver-fat comparison had p=0.2438, while the triglyceride comparison had p=0.113. Neither met the usual 0.05 threshold for statistical significance.

MediciNova is a La Jolla, California, clinical-stage developer of small-molecule drugs for inflammatory, fibrotic and neurological diseases, with several programs in human trials.

MediciNova NASDAQMNOV closed at US$2.58 on Nasdaq on Sept. 25, as of 4 p.m. EDT. That was its last regular-session close before Monday's topline.

The Liver-Fat And Triglyceride Measures Both Fell Short

The trial randomized patients with fatty liver disease, high triglycerides and type 2 diabetes in a one-to-one comparison of tipelukast at 500 mg a day with placebo. MediciNova's Sept. 28 topline said the mean liver-fat CAP score fell by 14.1 dB/m on the drug and 4.3 dB/m on placebo. The difference between groups was not statistically significant.

Fasting triglycerides fell by a mean 45.8 mg/dL on tipelukast and 14.4 mg/dL on placebo at week 24. The company reported an earlier triglyceride advantage at week four, with p=0.015, but the week-24 result was the prespecified primary comparison.

HDL cholesterol increased by 3.3 mg/dL on tipelukast while declining by 2.4 mg/dL on placebo. The resulting 5.7 mg/dL difference had p=0.0048. HDL particle concentration also favoured the drug by 4.52 micromoles per litre, with p=0.018, according to the same release.

Mean body weight fell by 4.91 pounds on drug and 0.55 pounds on placebo, a difference that was not statistically significant at p=0.082. MediciNova said treatment-related adverse events were mild to moderate and reported no drug-related serious adverse events.

"We will continue detailed analyses of the study data and assess the next stage of clinical development, including the appropriate patient population, endpoints, and sample size," MediciNova said in its Sept. 28 release.

Cash And A Liver-Disease Peer Frame The Next Test

The two company notices do not cite FDA agreement on this trial's endpoint design. That leaves a larger study's population and main measure open while MediciNova examines whether the lipid changes warrant further testing.

MediciNova's Aug. 13 quarterly filing showed US$25.4 million in cash and equivalents at June 30, 2026. That balance alone does not establish the cost or funding duration of another trial.

A listed liver-disease comparator is Madrigal Pharmaceuticals, Inc. NASDAQMDGL. Its March 14, 2024 approval release says the FDA granted accelerated approval to Rezdiffra for adults with noncirrhotic steatohepatitis and moderate to advanced fibrosis. That is a different disease stage and treatment setting from MediciNova's diabetes-associated fatty-liver trial, so the two readouts cannot be compared directly.

The broader biotech sector entered Monday with the iShares Biotechnology ETF NASDAQIBB at US$209.77 at the Sept. 25 close, as of 4 p.m. EDT. MediciNova's Friday close preceded its own results, leaving Monday's Nasdaq session to establish the first regular-session reaction.

Read more: Gossamer Bio submits seralutinib NDA after Phase 3 endpoint miss

Read more: Eli Lilly and Company wins FDA approval for weekly Onswik insulin

The Nasdaq session on Monday, Sept. 28 will establish the first closing price after the readout and show how investors weigh the missed primary comparisons against the HDL gains. The Sept. 28 release gives no date for its deeper analysis or a decision on another trial.